The presentation of new data at a major conference like ACR 2024 can positively impact Amgen's stock price. The potential of UPLIZNA® as a treatment for IgG4-RD and the improved infusion times for KRYSTEXXA® are likely to be seen as positive developments by investors, potentially leading to a short-term increase in stock price.